These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Rational therapeutic approaches to progressive supranuclear palsy. Stamelou M; de Silva R; Arias-Carrión O; Boura E; Höllerhage M; Oertel WH; Müller U; Höglinger GU Brain; 2010 Jun; 133(Pt 6):1578-90. PubMed ID: 20472654 [TBL] [Abstract][Full Text] [Related]
10. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy. Jellinger KA Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518 [TBL] [Abstract][Full Text] [Related]
11. The diagnosis of progressive supranuclear palsy: current opinions and challenges. Ali F; Josephs K Expert Rev Neurother; 2018 Jul; 18(7):603-616. PubMed ID: 29902389 [TBL] [Abstract][Full Text] [Related]
12. Amantadine-induced myoclonus in a patient with progressive supranuclear palsy. Yarnall AJ; Burn DJ Age Ageing; 2012 Sep; 41(5):695-6. PubMed ID: 22421702 [TBL] [Abstract][Full Text] [Related]
13. Thalamic hypoperfusion in early stage of progressive supranuclear palsy (Richardson's syndrome): report of an autopsy-confirmed case. Kobayashi Z; Akaza M; Ishihara S; Tomimitsu H; Inadome Y; Arai T; Akiyama H; Shintani S J Neurol Sci; 2013 Dec; 335(1-2):224-7. PubMed ID: 24075472 [TBL] [Abstract][Full Text] [Related]